Histiocytoses converge through common pathways.
暂无分享,去创建一个
[1] Michael M. Henry,et al. ALK+ histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. , 2021, Blood.
[2] B. Rollins,et al. Histiocytosis , 2021, The Lancet.
[3] Masayuki Yoshida,et al. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology. , 2020, The American journal of surgical pathology.
[4] E. Jaffe,et al. ALK-positive histiocytosis with KIF5B-ALK fusion in an adult female , 2019, Haematologica.
[5] E. Jaffe,et al. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups , 2019, Haematologica.
[6] Ahmet Dogan,et al. Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms , 2019, Nature.
[7] C. Fletcher,et al. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma , 2019, Modern Pathology.
[8] S. Yuen,et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion , 2018, Modern Pathology.
[9] N. Harris,et al. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. , 2008, Blood.
[10] J. Chan,et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. , 2008, Blood.